NEW YORK (GenomeWeb News) – Randox Laboratories has agreed to a non-exclusive license for Seegene's technology for use with its biochip array platform, Seegene said today.

The agreement will give Randox access to Seegene's Dual Priming Oligo technology, which it will use to develop high-throughput diagnostic screening panels to detect a variety of pathogens that cause either respiratory or sexually transmitted diseases from one sample.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.

George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.

A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.

The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.